PAREXEL International Corp.

195 West Street,
Waltham, Massachusetts 02451
United States,
(781) 487-9900
www.parexel.com

PAREXEL International Corp. is a global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and has approximately 19,600 employees.

M&A Summary

Buy vs Sell

Year ≤ '13 '14 '15 '16 '17 '18 T
Buy (1.0/yr) # 11 2 - 2 1 - 16
vol $176M $176M
Sell (0.0/yr) # 1 - - - - - 1
  17

Top M&A Advisors

Financial Deals
Sign-up to View
1
Legal Deals
Join to Access.

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Liquent, Inc.
$72M (2012-12-21)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View

PAREXEL International was acquired by Pamplona Capital Management - Private Equity on June 20, 2017.

PAREXEL International has acquired 16 companies of its own, including 5 in the last 5 years. A total of 1 acquisition came from private equity firms. It has also divested 1 asset.

PAREXEL International’s largest acquisition to date was in 2012, when it acquired Liquent for $72M. PAREXEL International has acquired in 5 different US states, and 5 countries. The Company’s most targeted sectors include life science (57%) and business services (13%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 406 life science companies that have made at least 1 acquisition, 14 have acquired at least 5 companies, and 2 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 30 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 6 platform acquisitions.

Join Mergr and gain access to PAREXEL International’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.4K Private Equity Firms
  • 121K M&A Transactions
  • 131K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.